fbpx
Title Image

WeekWatch – ‘the numbers in Pfizer’s press release last week were promising’ November 2020

WeekWatch – ‘the numbers in Pfizer’s press release last week were promising’ November 2020

Six countries, 44,000 trial participants, 90% effective: the numbers in Pfizer’s press release last week were promising. On Monday, the US drug giant announced that the late-stage trial of its COVID-19 vaccine, being co-produced with Germany’s BioNTech, had produced some strong results.

The news fuelled a rally in many risk assets as, for the first time since March, investors saw a path to normality that looked a little clearer.

Today’s announcement by Moderna of a vaccine with 94.5% efficacy is doubly encouraging.

“The uncertainty that has plagued us through most of 2020 has dramatically declined,” said Johanna Kyrklund, Chief Investment Officer at Schroders and manager of the St. James’s Place Managed Growth fund.

However, last week’s market optimism wasn’t universally felt. The most striking feature of the rally was the divergence between stocks that performed well and those that lagged. Companies whose share prices have struggled throughout the pandemic, such as those in the hospitality or travel sectors, enjoyed a return to good fortune. Cruise-ship operator Carnival Corp’s shares ended Monday up 39% over the day, for example, and British Airways owner IAG saw its share price rise over 40% throughout the week.

On the other hand, some of the “stay-at-home” stocks that have been beneficiaries of the pandemic saw their share prices decline. Some of the these were the high-flying technology companies whose
revenues have grown in 2020 thanks to more people shopping online and working from home.

Towards the end of last week, enthusiasm about the vaccine seemed to have been dampened by evidence that COVID-19 cases are still on the rise in many areas. In the US, for example, new cases
reached their highest level yet on Friday, at 184,000 per day.

We may see similar peaks and troughs across markets this week as they react to the news of Moderna’s vaccine trials.

Widespread adoption of a successful vaccine is some way off even in the best-case scenario, noted AXA Investment Management, a fund manager for St. James’s Place: “Even with a successful vaccine, a mass roll-out will face logistical challenges and could take longer than the market is expecting.”

While encouraging, the vaccine is unlikely to boost economic activity until next year, said Capital Economics. It added that given the breakthrough has led to “light at the end of the tunnel” and a belief that the virus can soon be controlled, it might encourage countries to impose more intense lockdowns in the interim.

So, even though last week’s announcement is undeniably good news, the best stance for investors to adopt is probably one of cautious optimism.

How should investors act now?

Given last week’s events in markets, some market observers are arguing that we’re at the start of a major market ‘rotation’, in which out-of-favour sectors begin to have their time in the sun. In that scenario, fast-growing technology stocks, and other strong performers during the pandemic, would begin to lag behind stocks that benefit more directly from economic recovery, such as banks and energy companies.

That may be the case. But given how difficult it is for investors to time such an event, the best course of action is to maintain a diversified set of investments that includes assets on both sides of the rotation, says Gavin McGhee, Wealth Management Consultant at St. James’s Place.

He adds: “You can’t rely on one particular investment style, sector, or market continuing to be the flavour of the month.”

Given this challenge, investors should resist the urge to change their approach on the back of major announcements like Pfizer or Moderna’s. One of the benefits of diversification is that it ensures portfolios aren’t too reliant on, or susceptible to, any single event.

“As fund managers we like to pretend that we have a crystal ball, but in reality, to build a portfolio, you need to consider a range of potential scenarios. You seek to make investments that can cope with multiple outcomes,” adds Schroders’ Johanna Kyrklund.

COVID-19 aside, there are plenty of potential sources of uncertainty ahead.

Investors were reminded of the strained relationship between the US and China on Friday, when the US issued a ban on American investors owning shares in Chinese firms that are suspected to have
links to the country’s military. The share prices of some of the Chinese companies named in the order dropped on the news.

Meanwhile, although the US election is behind us, there are still political risks in Washington. The Trump campaign’s legal challenges to the result of that contest are one source of concern, because even if they have little material impact on the transfer of power, they might mean that the current administration is less focussed on passing a new fiscal stimulus package.

Finally, Brexit trade deal talks are approaching their final stage. Although the UK’s chief negotiator, David Frost, said that there has been progress in recent days, he has little to show for it yet. Over the weekend, Ireland’s foreign minister told reporters that the two sides have to make progress this week if a deal is to be successful.

 

Axa and Schroders are fund managers for St. James’s Place.

The information contained is correct as at the date of the article. The information contained does not constitute investment advice and is not intended to state, indicate or imply that current or past results are indicative of future results or expectations. Where the opinions of third parties are offered, these may not necessarily reflect those of St. James’s Place.

FTSE International Limited (“FTSE”) © FTSE 2020. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under licence. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

© S&P Dow Jones LLC 2020; all rights reserved

The ‘St. James’s Place Partnership’ and the titles ‘Partner’ and ‘Partner Practice’ are marketing terms used to describe St. James’s Place representatives. Members of the St. James’s Place Partnership in the UK represent St. James’s Place Wealth Management plc, which is authorised and regulated by the Financial Conduct Authority. St. James’s Place Wealth Management plc Registered Office: St. James’s Place House, 1 Tetbury Road, Cirencester, Gloucestershire, GL7 1FP, United Kingdom. Registered in England Number 4113955.

7 Whiting Street
Bury St Edmunds
Suffolk, IP33 1NX
01284 703422
abbeygatewm@sjpp.co.uk

Registered in England and Wales
Company No.06803554

The Partner Practice is an Appointed Representative of and represents only St. James's Place Wealth Management plc (which is authorised and regulated by the Financial Conduct Authority) for the purpose of advising solely on the group's wealth management products and services, more details of which are set out on the group's website www.sjp.co.uk/products. The 'St. James's Place Partnership' and the titles 'Partner' and 'Partner Practice' are marketing terms used to describe St. James's Place representatives.